Derm Topics

Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab
Key Tips for Dermatologists in Prescribing and Managing JAK Inhibitors
JAK InhibitorsNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Neal Bhatia (a board-certified Dermatologist who serves as Director of Clinical Dermatology at Therapeutics Clinical Research ) about the latest with JAK inhibitors. Watch as he summarizes the most recent trials, approvals, and developments. Plus why doctors shouldn't be afraid to dive in w …
JAK Inhibitors
Skincare Mondays | Data-Driven Dermatology Improves Patient Outcomes
data driven dermatologyData-Driven Dermatology Improves Patient Outcomes The use of real-world data and real-world evidence to inform health care decisions is increasing. While randomized controlled trials (RCTs) are still the gold standard for evidence-based medicine, the strict inclusion/exclusion criteria and tightly controlled conditions limit their generalizability to real-world clinical practice.  Real worl …
data driven dermatology
Eosinophilia – Pop Quiz 8/5
A 55-year-old male with a medical history significant for type-2 diabetes mellitus, hypertension, and 25 pack/year smoking history undergoes percutaneous coronary intervention for an acute coronary event. He is admitted to the ICU where his exam is significant for the findings seen in the image. Lab evaluation reveals eosinophilia and acute kidney injury. What is the most likely diagnosis? …